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AbstrAct
Objective
To examine associations between birth defects and 
cancer from birth into adulthood.
Design
Population based nested case-control study.
setting
Nationwide health registries in Denmark, Finland, 
Norway, and Sweden.
ParticiPants
62 295 cancer cases (0-46 years) and 724 542 
frequency matched controls (matched on country and 
birth year), born between 1967 and 2014.
Main OutcOMe Measures
Relative risk of cancer in relation to major birth 
defects, estimated as odds ratios with 99% 
confidence intervals from logistic regression models.
results
Altogether, 3.5% (2160/62 295) of cases and 2.2% 
(15 826/724 542) of controls were born with major 
birth defects. The odds ratio of cancer for people with 
major birth defects compared with those without 
was 1.74 (99% confidence interval 1.63 to 1.84). 
For individuals with non-chromosomal birth defects, 
the odds ratio of cancer was 1.54 (1.44 to 1.64); for 
those with chromosomal anomalies, the odds ratio 
was 5.53 (4.67 to 6.54). Many structural birth defects 
were associated with later cancer in the same organ 
system or anatomical location, such as defects of the 
eye, nervous system, and urinary organs. The odds 
ratio of cancer increased with number of defects and 
decreased with age, for both non-chromosomal and 
chromosomal anomalies. The odds ratio of cancer in 
people with any non-chromosomal birth defect was 
lower in adults (≥20 years: 1.21, 1.09 to 1.33) than 
in adolescents (15-19 years: 1.58, 1.31 to 1.90) and 
children (0-14 years: 2.03, 1.85 to 2.23). The relative 
overall cancer risk among adults with chromosomal 
anomalies was markedly reduced from 11.3 (9.35 
to 13.8) in children to 1.50 (1.01 to 2.24). Among 
adults, skeletal dysplasia (odds ratio 3.54, 1.54 to 
8.15), nervous system defects (1.76, 1.16 to 2.65), 
chromosomal anomalies (1.50, 1.01 to 2.24), genital 
organs defects (1.43, 1.14 to 1.78), and congenital 
heart defects (1.28, 1.02 to 1.59) were associated 
with overall cancer risk.
cOnclusiOns
The increased risk of cancer in individuals with birth 
defects persisted into adulthood, both for non-
chromosomal and chromosomal anomalies. Further 
studies on the molecular mechanisms involved are 
warranted.
Introduction
Globally, in 2017, birth defects and childhood cancer 
were the third and ninth top causes of childhood 
disease burden, respectively (excluding injuries and 
perinatal diseases).1 Approximately 3% of liveborn 
children in the Nordic countries are born with major 
birth defects.2 Birth defects, particularly chromosomal 
anomalies but also non-chromosomal defects, are 
one of the strongest and most consistent risk factors 
for childhood cancers.3-6 This suggests that birth 
defects and childhood cancer may have a common 
aetiology—genetic, environmental, or a combination. 
Few established risk factors exist for both birth defects 
and childhood cancer,6 7 and identifying specific 
birth defects and childhood cancer associations can 
facilitate further research on common factors that 
affect disease development.
The reported excess risk of cancer in children with 
birth defects varies by type of anomaly. Children 
with Down’s syndrome are, for instance, at increased 
risk of developing leukaemia, whereas the elevated 
risk of cancer in children with non-chromosomal 
defects seems to be driven mostly by embryonal 
tumours.3 4 Several specific associations have been 
observed in previous studies, and the gradient in risk 
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WhAt Is AlreAdy knoWn on thIs topIc
Being born with a birth defect is one of the strongest risk factors for childhood 
cancer
Several specific birth defect-cancer associations have been identified, and 
increasing risk with increasing number of birth defects has been reported
The risk of cancer is higher at younger ages, but few studies have investigated 
cancer risk beyond childhood and adolescence
WhAt thIs study Adds
Many structural birth defects were associated with later cancer in the same organ 
system or anatomical location
The increased cancer risk in individuals with birth defects persisted into 
adulthood
In particular, the increased risk in adults remained for those born with congenital 
heart defects, genital organs defects, chromosomal anomalies, nervous system 
defects, and skeletal dysplasia
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seems to increase with number of birth defects.3 5 8 
Risk of cancer is highest in young children, but few 
studies have investigated risk beyond childhood and 
adolescence.8-14 Thus, the contribution of birth defects 
to risk of cancer in adulthood is to a large degree 
unknown.15
The rarity of both birth defects and childhood cancers 
makes studying these associations challenging, and 
very large studies are needed to identify enough 
individuals with birth defects to allow stable estimates 
of cancer risk. In this large population based nested 
case-control study of children, adolescents, and adults 
(age 0-46 years), we linked national health registries 
in four Nordic countries to examine the association 
between major birth defects and cancer, both overall 
and for specific types, and stratified by age at diagnosis 
of cancer. We aimed to identify associations between 
birth defects and cancer, assess whether risk of 
cancer changed with the number of birth defects, and 




All Nordic countries have national population based 
health registries that are based on compulsory 
notification from healthcare providers, and access to 
healthcare is universal and independent of income. 
Information on birth defects came from the medical 
birth registries, containing information on all births in 
Denmark, Finland, Norway, and Sweden since 1973, 
1987, 1967, and 1973, respectively.16 The Danish 
National Patient Registry (since 1977), the Register 
of Congenital Malformations at the Finnish Institute 
for Health and Welfare (since 1963), and the Swedish 
National Patient Register at the Swedish National 
Board of Health and Welfare (since 1964) provided 
additional information on birth defects.17-19 As we 
were interested in major birth defects, we used only 
inpatient diagnoses during the first year of life from 
the patient registries. We obtained information on 
cancer from the cancer registries in Denmark, Finland, 
Norway, and Sweden, covering the entire populations 
since 1943, 1953, 1953, and 1958, respectively.20 
Information on deaths and emigration came from the 
national population registries. Figure 1 shows the data 
sources for the research database.
study population
Every resident in the Nordic countries is assigned a 
country specific unique identification number used 
in all administrative and medical registries, which 
makes accurate record linkage possible. Cases were 
defined as liveborn individuals in the birth registries, 
with a subsequent cancer diagnosis recorded in the 
cancer registries. We selected controls from among 
people who were alive, living in the country, and with 
no cancer diagnosis by the end of follow-up (2013 in 
Denmark, Finland, and Norway; 2014 in Sweden). We 
frequency matched them on country and year of birth 
(case-control ratio 1:10). After exclusion of ineligible 
cases (but keeping the controls), the study population 
included 62 295 cases and 724 542 controls.
classification of cancer
In Norway and Finland, and for leukaemia and 
lymphoma in Denmark, cases of cancer were classified 
according to the ICD-O-3 (international classification 
of diseases for oncology, third edition).21 In Denmark, 
except for leukaemia and lymphoma, we used the 
ICD-10 (international classification of diseases, 10th 
revision) codes and ICD-O-3 morphology codes.22 
In Sweden, we used ICD-7 codes, combined with 
morphology diagnosis coded by ICD-O-2/3 or the 
WHO/HS/CANC/24.1 classification.23 We excluded 
non-malignant neoplasms, except for tumours in 
the urinary tract or central nervous system and other 
intracranial tumours (other endocrine glands), and 
cases without verified morphology, except for central 
nervous system and other intracranial tumours. We 
also excluded basal cell carcinomas. We classified 
cases in ICD-10 groups,24 except for leukaemia and 
lymphoma, which we classified in ICD-O-3 morphology 
groups 25 (supplementary table A).
National population registries Cancer registries Medical birth registries
Information on deaths
and emigration




62 295   Selected cases 724 524   Controls
786 819
Fig 1 | Data sources in four nordic countries. controls were frequency matched on birth year in each country (1:10 
case-control ratio with 100% successful matching). some benign cases (for example, cervical precursor lesions) were 
later excluded from research database, resulting in final case-control ratio of 1:12
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classification of major birth defects
The exposure of interest was major birth defects, 
classified in subgroups, registered in the birth registries, 
congenital malformation registry, or patient registries. 
We classified birth defects, and excluded minor 
birth defects, by using the definitions applied by the 
European network of population-based registries for the 
epidemiological surveillance of congenital anomalies 
(EUROCAT)26 (using ICD-10 codes, but not including 
the British Paediatric Association exten sions to ICD-
10 as these codes were not available in all countries). 
In Denmark, the birth defects were coded according to 
ICD-8 throughout 1993 and ICD-10 thereafter.17 The 
Finnish Register of Congenital Malformations coded 
birth defects according to ICD-9 Atlanta modification 
from 1986 onwards with the retrospective inclusion of 
ICD-10 codes from 1996. In Norway, the birth defects 
were coded according to ICD-8 during 1967-98, with 
the addition of some internally generated codes, and 
ICD-10 from 1999. In Sweden, the birth defects were 
coded according to the Swedish versions of ICD-8 
during 1973-86, ICD-9 during 1987-96, and ICD-10 
from 1997 onwards. We defined single birth defects, 
multiple defects within the same anatomical subgroup, 
and multiple defects when these were part of a sequence 
as isolated birth defects. We defined multiple birth 
defects from different anatomical subgroups, and not 
part of a sequence, as multiple birth defects according 
to the algorithm described by Garne et al.27
statistical analysis
We used unconditional logistic regression models to 
obtain odds ratios of overall and specific types of cancer 
with 99% confidence intervals comparing individuals 
with major birth defects with those without major birth 
defects.28 Because cancer is relatively rare among both 
exposed (individuals with major birth defects) and 
unexposed people, we interpreted the odds ratios as 
approximations of relative risks.29 30 We adjusted odds 
ratios for the matching factors (country and birth year) 
and sex. Other possible confounders evaluated were in 
vitro fertilisation, maternal age, and smoking. We did 
not adjust for intermediate factors (birth weight and 
preterm birth) in order to estimate the total effect of 
birth defects on risk of cancer. Confounder selection is 
illustrated in a directed acyclic graph (supplementary 
figure A). We stratified by age at cancer diagnosis to 
evaluate risk of cancer at different ages. We assessed 
the association between number of major birth defects 
(1, 2, 3, or ≥4) as a categorical exposure and cancer and 
tested for linear trend by using orthogonal polynomial 
contrasts.31 We analysed chromosomal anomalies and 
non-chromosomal birth defects separately. For selected 
analyses with enough cases, we stratified by country to 
evaluate whether the findings were consistent. When 
evaluating smoking as possible confounder, in the 
time period when this information was available, we 
used a complete case approach for handling missing 
data.32 We chose 99% confidence intervals to reduce 
the probability of false positive results. We used Stata 
version 16 for all analyses.
Patient and public involvement
No patients or members of the public were involved 
in the study design, interpretation of results, or 
development of dissemination strategy. This study was 
entirely based on data already recorded in mandatory 
population based registers and databases.
results
Table 1 shows characteristics of the population. Age 
at diagnosis of cancer ranged from 0 to 46 years, with 
a median of 23 (interquartile range 10-31) years. 
Thirty two per cent (19 881/62 295) of the cases were 
below 15 years of age, and 58% (36 068/62 295) 
were above 20. As the registries were established in 
different years, the age distribution differed between 
countries, with the oldest population in Norway. The 
median maternal age at delivery was 27 (23-31) years. 
Altogether, 2160 (3.5%) of cases and 15 826 (2.2%) 
of controls were registered with a major birth defect. 
The most common were congenital heart defects, 
limb defects, and genital anomalies (table 2). The 
three largest malignancy groups were lymphoid and 
haematopoietic malignancies, genitourinary cancers, 
and central nervous system tumours (fig 2).
risk of overall cancer in people with birth defects
We observed an increase in overall cancer risk in 
people with any major birth defect compared with 
those without major birth defects (odds ratio 1.74, 
99% confidence interval 1.63 to 1.84) (table 2). The 
odds ratio was highest for people with chromosomal 
anomalies (5.53, 4.67 to 6.54), with the highest overall 
relative cancer risk for those with Down’s syndrome 
(6.08, 5.06 to 7.30). Risk of cancer was also elevated 
in people with non-chromosomal birth defects (odds 
ratio 1.54, 1.44 to 1.64), with the highest relative risks 
of any cancer in individuals with genetic syndromes/
microdeletions (5.44, 3.57 to 8.28), nervous system 
defects (4.76, 3.89 to 5.83), and skeletal dysplasia 
(3.34, 1.97 to 5.67). Furthermore, we observed an 
increased risk of cancer for people with birth defects of 
the eye, digestive system, urinary organs, heart, genital 
organs, and limbs and other anomalies/syndromes.
risk of specific cancer types in people with birth 
defects
Among people with non-chromosomal birth defects, 
we observed the highest relative risks of cancers of 
urinary organs (mainly kidney cancer) (odds ratio 2.7, 
2.1 to 3.5), peripheral nerves and autonomic nervous 
system (2.4, 1.5 to 3.9), and central nervous system 
(2.3, 2.0 to 2.6) compared with people without major 
birth defects (fig 2). In addition, we observed increased 
risks of cancers of digestive organs (mainly liver), soft 
tissue, genital organs, nose/sinuses, thyroid and other 
endocrine glands, and lymphoid and haematopoietic 
tissue (non-Hodgkin’s lymphoma in particular) 
and other or unspecified cancer. For people with 
chromosomal anomalies, we observed an increased 
risk of cancers of lymphoid and haematopoietic 
tissue, with the highest risk observed for acute 
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myeloid leukaemia (odds ratio 88, 67 to 117) (fig 3). 
In addition, we saw increased risks for eye, testicular, 
and kidney cancer.
risk of overall cancer in people with birth defects 
stratified by age at diagnosis
The overall risk of cancer associated with birth 
defects was elevated in all age groups (0-4, 5-9, 
10-14, 15-19, ≥20 years) (fig 4). However, the odds 
ratios decreased with age at diagnosis for both non-
chromosomal and chromosomal anomalies. The 
overall odds ratio of cancer in people with non-
chromosomal birth defects was lower in adults (≥20 
years: 1.21, 1.09 to 1.33) than in adolescents (15-
19 years: 1.58, 1.31 to 1.90) and children (0-14 
years: 2.03, 1.85 to 2.23) (supplementary table B). 
For skeletal dysplasia and congenital heart defects, 
the reduction in odds ratio in adults compared with 
table 1 | characteristics of study population in Denmark (1977-2013), Finland (1987-2013), norway (1967-2013), and 
sweden (1973-2014). values are numbers (percentages)
characteristics cases (n=62 295) controls (n=724 542)
Major birth defects 2160 (3.5) 15 826 (2.2)
Sex*:
 Male 30 352 (48.7) 371 313 (51.2)
 Female 31 943 (51.3) 353 229 (48.8)
Birth weight, g:
 <2500 2565 (4.1) 29 464 (4.1)
 2500-3999 48 211 (77.4) 570 204 (78.7)
 ≥4000 11 353 (18.2) 123 009 (17.0)
 Missing 166 (0.3) 1865 (0.3)
Gestational age, weeks:
 <37 3329 (5.3) 37 173 (5.1)
 37-40 38 833 (62.3) 460 388 (63.5)
 ≥41 18 220 (29.2) 207 066 (28.6)
 Missing 1913 (3.1) 19 915 (2.7)
Maternal smoking†:
 No 14 745 (23.7) 197 724 (27.3)
 Yes 3869 (6.2) 57 622 (8.0)
 Missing 43 681 (70.1) 469 196 (64.8)
 Missing‡ 1702/20 316 (8.4) 24 291/279 291 (8.7)
Maternal age, years:
 <25 20 460 (32.8) 236 312 (32.6)
 25-29 22 137 (35.5) 260 778 (36.0)
 30-34 13 603 (21.8) 159 422 (22.0)
 ≥35 6095 (9.8) 68 030 (9.4)
In vitro fertilisation§:
 No 12 356 (19.8) 126 859 (17.5)
 Yes 159 (0.3) 1265 (0.2)
 Missing 49 780 (79.9) 596 418 (82.3)
Year of birth:
 <1970 5596 (9.0) 48 412 (6.7)
 1970-79 23 858 (38.3) 253 884 (35.0)
 1980-89 17 413 (28.0) 250 660 (34.6)
 1990-99 10 071 (16.2) 115 998 (16.0)
 2000-09 4612 (7.4) 47 621 (6.6)
 ≥2010 745 (1.2) 7967 (1.1)
Age at primary cancer diagnosis, years¶:
 0-4 10 362 (16.6) -
 5-9 5057 (8.1) -
 10-14 4462 (7.2) -
 15-19 6346 (10.2) -
 20-29 16 977 (27.3) -
 30-39 15 692 (25.2) -
 ≥40 3399 (5.5) -
Year of primary cancer diagnosis¶:
 <1980 1320 (2.1) -
 1980-89 3970 (6.4) -
 1990-99 10 424 (16.7) -
 2000-09 24 924 (40.0) -
 2010-14 21 657 (34.8) -
*Differences between cases and controls were due to sex ratio at birth and different cancer risk for males and females in study population (aged 0-46 
years).
†Available from 1991 in Denmark, 1987 in Finland, 1998 in Norway, and 1982 in Sweden.
‡Percentage missing in time period when this information was recorded.
§Reported in 1990-2013 in Finland, 1984-2013 in Norway, and 1995-2014 in Sweden; not included for Denmark. Missingness in registration period 
cannot be calculated.
¶Reported only for cases.
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children was less pronounced than for most other 
defects (skeletal dysplasia: adults 3.54 (1.54 to 8.15) 
versus children 3.59 (1.74 to 7.42); congenital heart 
defects: adults 1.28 (1.02 to 1.59) versus children 
1.53 (1.26 to 1.86)). The relative overall cancer risk 
among adults with chromosomal anomalies was 
markedly reduced (odds ratio 1.50 (1.01 to 2.24) 
in adults versus 11.3 (9.35 to 13.8) in children). In 
contrast, genital birth defects were associated with 
a higher relative risk of cancer among adults (odds 
ratio 1.43, 1.14 to 1.78) than adolescents (1.04, 
0.59 to 1.83) and children (1.25, 0.92 to 1.70). The 
highest relative risk of cancer among adults was for 
people with skeletal dysplasia (3.5-fold) followed by 
those with nervous system defects (odds ratio 1.76, 
1.16 to 2.65). For birth defects of the eye, digestive 
system, respiratory system, limbs, abdominal wall, 
and urinary organs and oro-facial clefts, we found no 
association with adult cancer.
risk of overall and specific cancer types in people 
with multiple birth defects
The risk of overall cancer in people with four or more 
non-chromosomal birth defects in different anatomical 
subgroups was nearly five times (odds ratio 4.9, 2.4 
to 10.1) the risk in those without major birth defects 
(fig 5). Among people with non-chromosomal birth 
defects, the odds ratio of overall cancer increased with 
the number of birth defects in different subgroups (P 
for trend<0.001), as did the odds ratios of soft tissue 
cancer, kidney cancer, and central nervous system 
tumours (P for trend<0.001). Among people with 
chromosomal anomalies, we observed an increase in 
risk of overall cancer and acute lymphatic leukaemia 
as the number of birth defects in different subgroups 
increased (P for trend<0.001).
associations between specific birth defects and 
specific types of cancers
We further explored the associations between specific 
major birth defects and specific cancers both in the 
entire study population and among adults (table 3). 
In the total population, the strongest associations 
were between defects involving genetic syndromes 
and microdeletions and cancers of urinary organs 
(odds ratio 35, 18 to 69), soft tissue (17, 5.6 to 49), 
and other endocrine glands (9.6, 3.0 to 31); between 
Down’s syndrome and lymphoid/ haematopoietic 
malignancies (19, 16 to 23); between anomalies of the 
eye and eye cancer (18, 7.5 to 44); between nervous 
system defects and central nervous system tumours 
(16, 13 to 21); and between urinary organs defects 
and cancer of urinary organs (8.0, 4.5 to 14). In the 
adult population, the strongest associations were 
between nervous system defects and cancers of urinary 
organs (odds ratio 14, 4.7 to 40) and other endocrine 
glands (5.8, 1.8 to 19); between Down’s syndrome 
and cancer of male genital organs (testicular cancer) 
(4.8, 2.7 to 8.6); between congenital heart defects and 
non-melanoma skin cancer (4.6, 1.6 to 13); between 
urinary organs defects and cancer of digestive organs 
(4.0, 1.2 to 13); between genital defects and cancer 
of digestive organs (2.3, 1.2 to 4.4) and male genital 
organs (testicular cancer) (1.9, 1.3 to 2.6); and 
between oro-facial clefts (mainly cleft lip) and breast 
cancer (2.3, 1.0 to 5.2).
table 2 | risk of overall cancer in people with any, or specific, major birth defects
birth defect*
no (%)
Odds ratio (99% ci)cases† (n=62 295) controls† (n=724 542)
All anomalies 2160/62 295 (3.47) 15 826/724 542 (2.18) 1.74 (1.63 to 1.84)
All anomalies excluding chromosomal anomalies 1818/61 953 (2.93) 15 067/723 783 (2.08) 1.54 (1.44 to 1.64)
specific sites
Nervous system 225/60 360 (0.37) 593/709 309 (0.08) 4.76 (3.89 to 5.83)
 Neural tube defects 90/60 225 (0.15) 216/708 932 (0.03) 5.00 (3.61 to 6.92)
Eye 60/60 195 (0.10) 373/709 089 (0.05) 2.07 (1.44 to 2.96)
Ear, face, and neck 8/60 143 (0.01) 92/708 808 (0.01) 1.13 (0.44 to 2.93)
Congenital heart defects 381/60 516 (0.63) 3512/712 228 (0.49) 1.42 (1.24 to 1.64)
Respiratory system 24/60 159 (0.04) 239/708 955 (0.03) 1.23 (0.71 to 2.15)
Oro-facial clefts 116/60 251 (0.19) 1242/709 958 (0.17) 1.12 (0.87 to 1.44)
 Cleft palate only 32/60 167 (0.05) 397/709 113 (0.06) 0.97 (0.60 to 1.56)
 Cleft lip with/without cleft palate 84/60 219 (0.14) 846/709 562 (0.12) 1.18 (0.88 to 1.59)
Digestive system 111/60 246 (0.18) 764/709 480 (0.11) 1.85 (1.43 to 2.41)
Abdominal wall defects 16/60 151 (0.03) 119/708 835 (0.02) 1.51 (0.76 to 3.01)
Urinary system 104/60 239 (0.17) 782/709 498 (0.11) 1.76 (1.34 to 2.30)
Genital organs 242/60 377 (0.40) 2538/711 254 (0.36) 1.30 (1.09 to 1.55)
Limb 292/60 427 (0.48) 2803/711 519 (0.39) 1.27 (1.09 to 1.49)
Skeletal dysplasia 30/60 165 (0.05) 114/708 830 (0.02) 3.34 (1.97 to 5.67)
Genetic syndromes and microdeletions 54/60 189 (0.09) 125/708 841 (0.02) 5.44 (3.57 to 8.28)
Chromosomal 342/60 477 (0.57) 759/709 475 (0.11) 5.53 (4.67 to 6.54)
 Down’s syndrome 301/60 436 (0.50) 604/709 320 (0.09) 6.08 (5.06 to 7.30)
Other anomalies/syndromes 424/60 559 (0.70) 2790/711 506 (0.39) 1.95 (1.70 to 2.23)
Odds ratios adjusted for matching variables (birth year and country) and sex. In all analyses for specific sites, other than for chromosomal anomalies, individuals with chromosomal anomalies 
were excluded. In all analyses, unexposed group was composed of individuals without major birth defects. Percentages of cases and controls are reported per analysis; study population consists 
of exposed (cases and controls with specific birth defect being analysed) and unexposed people (cases and controls without major birth defects).
*Categorised according to EUROCAT.
†Individuals with more than one diagnosis can be included in more than one sub-category; thus, the totals do not sum up to 2160.
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Mouth, pharynx
    Tongue
    Mouth, other
    Salivary glands




  Small intestine
  Colon




  Nose, sinuses
  Lung, trachea










  Cervix uteri
  Corpus uteri
  Uterus, other







  Kidney (excluding renal pelvis)







  Hodgkin’s lymphoma
  Non-Hodgkin’s lymphoma
  Immunoproliferative disease
  Acute lymphatic leukaemia
  Chronic lymphatic leukaemia
  Other lymphatic leukaemia
  Acute myeloid leukaemia
  Chronic myeloid leukaemia
  Other myeloid leukaemia
  Leukaemia, cell unspecified
  Other
1.3 (0.7 to 2.5)
2.2 (0.8 to 5.9)
0.8 (0.1 to 5.2)
0.8 (0.2 to 3.0)
1.8 (0.6 to 5.9)
1.5 (1.1 to 2.0)
4.1 (0.6 to 27)
1.9 (0.7 to 5.6)
1.8 (0.4 to 8.0)
0.9 (0.5 to 1.6)
1.1 (0.4 to 2.8)
2.9 (1.7 to 4.7)
1.9 (0.6 to 5.6)
1.7 (0.9 to 3.0)
3.2 (1.1 to 9.4)
1.5 (0.7 to 3.2)
1.4 (0.2 to 8.9)
1.4 (0.9 to 2.1)
0.9 (0.7 to 1.2)
1.9 (1.0 to 3.4)
4.5 (0.3 to 67)
2.4 (1.5 to 3.9)
1.7 (1.2 to 2.5)
1.3 (0.9 to 1.8)
1.4 (1.1 to 2.0)
3.1 (0.8 to 12)
0.9 (0.6 to 1.5)
0.5 (0.0 to 7.2)
12.0 (2.2 to 61)
2.7 (1.7 to 4.3)
2.1 (0.2 to 29)
1.4 (1.1 to 1.7)
1.2 (0.1 to 17)
1.4 (1.1 to 1.6)
3.8 (1.1 to 13)
2.7 (2.1 to 3.5)
2.9 (2.2 to 3.8)
1.8 (0.9 to 3.7)
1.2 (0.7 to 2.1)
2.3 (2.0 to 2.6)
1.6 (1.1 to 2.3)
2.0 (1.5 to 2.6)
2.2 (1.2 to 4.1)
1.2 (1.0 to 1.4)
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Fig 2 | risk of specific cancers in people with any major non-chromosomal birth defects among 61 953 cases and 723 783 controls. Odds ratios (Ors) 
adjusted for matching variables (birth year and country) and sex. cancer sites classified in icD-10 groups; sites with no co-occurring birth defects 
and cancers are not included. Ors for cancer of urinary systems, central nervous system, and other endocrine glands are presented for benign and 
malignant cases combined. separate effect estimates for malignant cases are 3.2 (2.4 to 4.1), 1.5 (1.2 to 1.9), and 2.8 (1.9 to 4.1) , respectively; 
estimates for benign cases are 0.7 (0.2 to 3.2), 3.3 (2.8 to 3.9), and 1.4 (0.9 to 2.1). ans=autonomic nervous system; bD=birth defect
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discussion
In this large population based nested case-control study 
in four Nordic countries, people with chromosomal 
and non-chromosomal birth defects were at increased 
risk of overall cancer into adulthood (investigated 
for individuals up to the age of 46). People with non-
chromosomal birth defects had an increased risk of 
cancer in several different organ systems, whereas the 
dominant malignancy for those with chromosomal 
anomalies was leukaemia. Many structural birth 
defects were associated with later cancer in the same 
organ system or anatomical location, and the relative 
risk of cancer increased with number of birth defects. 
Although the associations generally were stronger in 
children than adults, they persisted into adulthood. 
For instance, compared with people without major 
birth defects, those with two of the most common birth 
defect groups, congenital heart defects and genital 
defects, had an increased risk of cancer as adults (≥20 
years).
strengths and limitations of study
Among the strengths of our study were the large 
number of cancer cases (including all cases among 
births registered in the medical birth registries in four 
Nordic countries) and the ability to assess risk of cancer 
in adulthood and adolescence, as well as childhood 
in the same population. The large population meant 
that we could also study the associations between 
several specific birth defects and specific cancers. 
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Fig 3 | risk of specific cancers in people with chromosomal birth defects (n=1101; 905 Down’s syndrome) among 60 477 cases and 709 475 
controls. Odds ratios (Ors) adjusted for matching variables (birth year and country) and sex. cancer sites classified in icD-10 groups; sites with no 
co-occurring chromosomal anomalies and cancers are not included. ans=autonomic nervous system; bD=birth defect
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Fig 4 | risk of any cancer in people with any, or specific, major birth defects, stratified by age at diagnosis. note that scales differ across figures. 
Odds ratios (Ors) are adjusted for matching variables (birth year and country) and sex. in all analyses for specific sites, other than for chromosomal 
anomalies, people with chromosomal anomalies were excluded. in all analyses, the unexposed group was composed of people without major birth 
defects. some age groups do not have an estimated Or owing to no co-occurring birth defect and cancer cases
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The linkages of comprehensive and compulsory 
population based databases gave reliable and almost 
complete information on cancer diagnoses.20 From 
the patient registries, we used only diagnoses of birth 
defects from inpatient registrations because of low 
validity of outpatient diagnoses.19 In addition, we 
limited diagnoses to those occurring in the first year 
of life for consistency of exposure criteria in all four 
countries. For Finland, the data are from the Register of 
Congenital Malformation, which uses diagnoses given 
in hospital inpatient and outpatient care. However, all 
cases with major birth defect are validated from the 
hospitals before being entered in the register. We did 
a sensitivity analysis in which we stratified on country 
during 1987-2013 when all countries had available 
data and found similar risk estimates for any cancer 
among children with non-chromosomal anomalies 
(odds ratios from 1.8 to 2.7). Also, the risk estimates 
for larger cancer groups were in the same direction, 
supporting the reported associations.
In our study, ascertainment of birth defects may 
have differed both over time and between countries. 
Ascertainment depends on type and severity, so most 
studies, including ours, exclude minor birth defects. 
Variation also exists in the degree of ascertainment of 
major birth defects, especially if defects are registered 
No of birth defects in
different main categories
1 32 ≥4










































































































































Fig 5 | risk of selected cancers in people with major birth defects according to number of major birth defects in 
different anatomical subgroups. results are presented separately for people with any birth defect (including 
chromosomal birth defects) and those with non-chromosomal defects only. Odds ratios (Ors) are adjusted for 
matching variables (birth year and country) and sex. results are presented for all cancers in individuals with 1, 2, 3, 
and ≥4 birth defects (bDs)
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birth defect* and cancer site†
total study population adults (≥20 years)
no of cases
no (%) cases  
with birth defects Odds ratio (99% ci) no of cases
no (%) cases with 
birth defects Odds ratio (99% ci)
nervous system
Main groups:
 Central nervous system‡ 10 067 139 (1.4) 16 (13 to 21) 3612 6 (0.2) 2.4 (0.83 to 6.9)
 Other endocrine glands 2484 15 (0.6) 7.7 (3.9 to 15) 1281 5 (0.4) 5.8 (1.8 to 19)
 Eye 859 5 (0.6) 6.7 (2.1 to 22) - - -
 Urinary organs 1948 10 (0.5) 6.2 (2.7 to 14) 690 6 (0.9) 14 (4.7 to 40)
 Thyroid gland 2038 7 (0.3) 4.6 (1.7 to 12) - - -
 Soft tissues 1593 6 (0.4) 4.4 (1.5 to 13) - - -
Subgroups:
 Urinary tract 371 5 (1.3) 18 (5.6 to 59) 279 5 (1.8) 26 (8.1 to 86)
 Kidney (excluding renal pelvis) 1577 5 (0.3) 3.8 (1.2 to 12) - - -
Neural tube defects
Main groups:
 Central nervous system 9979 51 (0.5) 16 (11.0 to 24) - - -
 Urinary organs 1944 6 (0.3) 10 (3.6 to 30) 689 5 (0.7) 26 (8.1 to 86)
 Other endocrine glands 2476 7 (0.3) 9.5 (3.5 to 26) - - -
Subgroups:
 Urinary tract 371 5 (1.3) 46 (14 to 151) 279 5 (1.8) 62 (19 to 204)
eye
Main groups:
 Eye 863 9 (1.0) 18 (7.5 to 44) - - -
 Urinary organs 1951 13 (0.7) 12 (6.0 to 26) - - -
Subgroups:
 Kidney (excluding renal pelvis) 1585 13 (0.8) 14 (6.9 to 30) - - -
congenital heart defects
Main groups:
 Skin, non-melanoma 533 7 (1.3) 3.5 (1.3 to 9.3) 412 6 (1.5) 4.6 (1.6 to 13)
 Lymphoid/ haematopoietic tissue 14 223 209 (1.5) 2.5 (2.1 to 3.0) 4700 19 (0.4) 1.1 (0.58 to 1.9)
 Urinary organs 1963 25 (1.3) 2.3 (1.4 to 3.9) - - -
 Female genital organs 4015 26 (0.6) 1.9 (1.1 to 3.1) 3705 23 (0.6) 1.9 (1.1 to 3.3)
 Male genital organs 6545 37 (0.6) 1.6 (1.1 to 2.5) 5740 31 (0.5) 1.7 (1.0 to 2.6)
 Central nervous system§ 10 010 82 (0.8) 1.5 (1.2 to 2.1) 3625 19 (0.5) 1.6 (0.87 to 2.9)
Subgroups:
 Acute myeloid leukaemia 1092 49 (4.5) 7.8 (5.3 to 11) - - -
 Leukaemia, cell unspecified 322 12 (3.7) 6.6 (3.1 to 14) - - -
 Liver 459 12 (2.6) 4.5 (2.1 to 9.5) - - -
 Ovary etc. 817 11 (1.3) 3.1 (1.4 to 6.7) 558 8 (1.4) 4.0 (1.6 to 10)
 Kidney (excluding renal pelvis) 1596 24 (1.5) 2.6 (1.5 to 4.4) - - -
 Acute lymphatic leukaemia 5021 90 (1.8) 2.5 (1.9 to 3.4) - - -
 Testis 6439 36 (0.6) 1.6 (1.0 to 2.5) 5667 30 (0.5) 1.6 (1.0 to 2.6)
Oro-facial clefts
Main groups:
 Breast 3589 11 (0.3) 2.3 (1.0 to 5.1) 3578 11 (0.3) 2.3 (1.0 to 5.2)
Subgroups: - - -
 Ovary etc 811 5 (0.6) 4.3 (1.3 to 14) - - -
Cleft palate only
Subgroups:
 Ovary etc 811 5 (0.6) 11 (3.4 to 36) - - -
Cleft lip with without cleft palate
Main groups:
 Other endocrine glands 2477 8 (0.3) 2.8 (1.1 to 7.1) - - -
 Breast 3587 9 (0.3) 2.8 (1.1 to 6.7) 3576 9 (0.3) 2.8 (1.1 to 6.7)
Digestive system
Main groups:
 Urinary organs 1947 9 (0.5) 4.0 (1.7 to 9.4) - - -
 Other endocrine glands 2479 10 (0.4) 3.7 (1.6 to 8.5) - - -
 Digestive organs 2683 8 (0.3) 3.1 (1.2 to 7.7) - - -
 Lymphoid/ haematopoietic tissue 14 064 50 (0.4) 2.9 (2.0 to 4.2) 4688 7 (0.1) 1.5 (0.58 to 4.1)
Subgroups:
 Liver 1050 7 (0.7) 5.5 (2.0 to 15) - - -
 Acute myeloid leukaemia 1580 8 (0.5) 4.2 (1.7 to 11) - - -
 Kidney (excluding renal pelvis) 2945 12 (0.4) 3.5 (1.7 to 7.5) - - -
 Non-Hodgkin’s lymphoma - - -
 Acute lymphatic leukaemia 4951 20 (0.4) 3.0 (1.7 to 5.4) - - -
table 3 | associations between specific major birth defects and specific cancer groups (with ≥5 co-occurring cases) among total study population and 
among adults (≥20 years). altogether, 104 associations, significant at 1% significance level, are reported after 264 analyses
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table 3 | continued
birth defect* and cancer site†
total study population adults (≥20 years)
no of cases
no (%) cases  
with birth defects Odds ratio (99% ci) no of cases
no (%) cases with 
birth defects Odds ratio (99% ci)
urinary
Main groups:
 Urinary organs 1958 20 (1.0) 8.0 (4.5 to 14) - - -
 Other endocrine glands 2480 11 (0.4) 4.2 (1.9 to 9.2) - - -
 Digestive organs 2684 9 (0.3) 3.9 (1.6 to 9.3) 2028 5 (0.2) 4.0 (1.2 to 13)
Subgroups:
 Kidney (excluding renal pelvis) 1589 17 (1.1) 8.0 (4.2 to 15) - - -
genital
Main groups:
 Urinary organs 1957 19 (1.0) 2.9 (1.6 to 5.2) - - -
 Digestive organs 2692 17 (0.6) 2.0 (1.0 to 3.7) 2038 15 (0.7) 2.3 (1.2 to 4.4)
 Male genital organs 6576 68 (1.0) 1.8 (1.3 to 2.5) 5770 61 (1.1) 1.9 (1.3 to 2.6)
Subgroups:
 Rectum, rectosigmoid 451 5 (1.1) 3.5 (1.1 to 11) 438 5 (1.1) 3.7 (1.1 to 12)
 Liver 452 5 (1.1) 3.3 (1.0 to 11) - - -
 Kidney (excluding renal pelvis) 1588 16 (1.0) 3.2 (1.7 to 6.2) - - -
 Testis 6469 66 (1.0) 1.8 (1.3 to 2.5) 5698 61 (1.1) 1.9 (1.3 to 2.6)
limb
Main groups:
 Thyroid gland 2048 17 (0.8) 2.4 (1.3 to 4.5) 1624 9 (0.6) 1.6 (0.69 to 3.9)
 Urinary organs 1956 18 (0.9) 2.3 (1.2 to 4.2) - - -
 Other endocrine glands 2489 20 (0.8) 2.1 (1.2 to 3.8) 1284 8 (0.6) 1.7 (0.7 to 4.4)
Subgroups:
 Kidney (excluding renal pelvis) 1588 16 (1.0) 2.5 (1.3 to 4.8) - - -
skeletal dysplasia
Main groups:
 Lymphoid/ haematopoietic tissue 14 026 12 (0.1) 4.3 (1.9 to 9.4) - - -
 Central nervous system 9934 6 (0.1) 3.4 (1.2 to 10) - - -
Subgroups:
 Non-Hodgkin’s lymphoma 2940 7 (0.2) 13 (4.9 to 37) - - -
genetic syndromes and microdeletions
Main groups:
 Urinary organs 1955 17 (0.9) 35 (18 to 69) - - -
 Soft tissues 1593 6 (0.4) 17 (5.6 to 49) - - -
 Other endocrine glands 2474 5 (0.2) 9.6 (3.0 to 31) - - -
 Central nervous system 9935 7 (0.1) 3.1 (1.1 to 8.3) - - -
 Lymphoid/ haematopoietic tissue 14 025 11 (0.1) 2.9 (1.3 to 6.5) - - -
Subgroups:
 Kidney (excluding renal pelvis) 1589 17 (1.1) 39 (20 to 77) - - -
Down’s syndrome
Main groups:
 Lymphoid/ haematopoietic tissue 14 269 255 (1.8) 19 (16 to 23) 4689 8 (0.2) 2.2 (0.86 to 5.4)
 Male genital organs 6532 24 (0.4) 4.8 (2.7 to 8.3) 5730 21 (0.4) 4.8 (2.7 to 8.6)
Subgroups:
 Acute myeloid leukaemia 1155 112 (9.7) 111 (84 to 148) - - -
 Leukaemia, cell unspecified 333 23 (6.9) 80 (45 to 141) - - -
 Acute lymphatic leukaemia 5034 103 (2.0) 22 (16 to 29) - - -
 Other myeloid leukaemia 440 7 (1.6) 18 (6.8 to 49.0) - - -
 Testis 6427 24 (0.4) 4.8 (2.8 to 8.4) 5658 21 (0.4) 4.9 (2.7 to 8.7)
Other anomalies/ syndromes
Main groups:
 Central nervous system¶ 10 084 156 (1.5) 4.3 (3.4 to 5.3) 3629 23 (0.6) 1.9 (1.1 to 3.2)
 Peripheral nerves and autonomic nervous system 505 7 (1.4) 3.6 (1.3 to 9.6) - - -
 Urinary organs 1961 23 (1.2) 3.2 (1.8 to 5.4) 690 6 (0.9) 2.4 (0.84 to 7.0)
 Soft tissues 1605 18 (1.1) 3.0 (1.6 to 5.6) - - -
 Bone 1421 11 (0.8) 2.2 (1.0 to 4.8) - - -
 Lymphoid/ haematopoietic tissue 14 100 86 (0.6) 1.6 (1.2 to 2.1) 4705 24 (0.5) 1.3 (0.79 to 2.3)
 Male genital organs 6547 39 (0.6) 1.5 (1.0 to 2.4) 5741 32 (0.6) 1.5 (0.92 to 2.3)
Subgroups:
 Kidney (excluding renal pelvis) 1595 23 (1.4) 4.0 (2.3 to 6.9) 416 6 (1.4) 4.4 (1.5 to 13)
 Acute myeloid leukaemia 1053 10 (0.9) 2.5 (1.1 to 5.7) - - -
 Acute lymphatic leukaemia 4961 30 (0.6) 1.6 (1.0 to 2.6) - - -
 Testis 6442 39 (0.6) 1.6 (1.0 to 2.4) 5669 32 (0.6) 1.5 (0.93 to 2.3)
Chromosomal anomalies are excluded from all birth defect groups other than Down’s syndrome. In all analyses, unexposed group was composed of individuals without major birth defects. Odds 
ratios adjusted for matching variables (birth year and country) and sex.
*Categorised according to EUROCAT.
†Categorised according to Cancer in Norway (2017)/NORDCAN.
‡Separate odds ratios and 99% CIs for malignant and benign cases: 7.8 (4.9 to 13) and 24 (18 to 33), respectively, in total study population; 3.9 (1.2 to 12), only benign cases, among adults.
§Separate odds ratios and 99% CIs for malignant and benign cases: 1.3 (0.8 to 2.0) and 2.0 (1.4 to 3.1), respectively, in total study population; 1.7 (0.8 to 3.9) and 1.5 (0.6 to 3.5), respectively, 
among adults.
¶Separate odds ratios and 99% CIs for malignant and benign cases: 2.3 (1.5 to 3.4) and 8.0 (6.2 to 10.3), respectively, in total study population; 0.8 (0.3 to 2.6) and 3.0 (1.6 to 5.5), 
respectively, among adults.
copyright.
 on 4 D
ecem
ber 2020 at H












J: first published as 10.1136/bm
j.m







12 doi: 10.1136/bmj.m4060 | BMJ 2020;371:m4060 | the bmj
only at or immediately after birth. Visibility of the 
defect at birth is associated with higher ascertainment 
than for less visible birth defects.33 34 However, 
under-ascertainment of birth defects is unlikely to be 
associated with later diagnosis of cancer and should 
generally bias associations towards the null. On the 
other hand, if cases among individuals aged under 
1 year are more likely to be diagnosed as having a 
birth defect than controls, the results may be biased 
away from the null. Although adjustments for in vitro 
fertilisation, maternal age, and maternal smoking 
habits did not change the results substantially 
(supplementary tables C, D, and E), we may lack 
information for other unknown confounders. For 
instance, we could not include information on parental 
income or education owing to strict data regulations in 
some study countries. Also, if the missingness of data 
on maternal smoking was not completely at random, 
this analysis may be biased. For some of the analyses 
of combinations of specific birth defects and cancers, 
statistical power was limited. Spurious associations 
resulting from multiple comparisons may also be a 
concern. Therefore, we attempted to evaluate patterns 
of associations with regard to aetiology and relevant 
biological mechanisms.
comparison with other studies
Previous studies have reported declining risk of 
cancer with age, but most were limited by size, shorter 
follow-up time, or both, and few were able to assess 
specific birth defects.8-13 35 36 Only three studies 
included adults, and these evaluated only nervous 
and circulatory system defects and congenital heart 
defects.14 35 36 In our study, we found that although 
the increase in overall cancer risk declined with age, 
it persisted into adulthood for both non-chromosomal 
and chromosomal anomalies. Furthermore, we were 
able to look at anatomical subgroups of birth defects 
and observed that the increased risk at younger ages 
was more pronounced for some subgroups, such 
as nervous system defects, genetic syndromes and 
microdeletions, and chromosomal anomalies. Most 
cancers associated with birth defects appear during 
childhood owing to the exposure being congenital 
and the typical latency of cancer. This is supported by 
odds ratios for cancer being higher during childhood 
(0-14 years) than adulthood (20 years or older). 
The exception was for people with defects in genital 
organs relative those without such defects, for which 
the odds ratio for cancer (one third of which were 
testicular) was 1.43 (99% confidence interval 1.14 
to 1.78) for adults compared with 1.25 (0.92 to 1.70) 
for children. The long latency could be explained by 
the current model for this tumour’s development, 
comprising genetic susceptibility for both genital 
organ defects and testicular cancer, combined with 
environmental factors exerting their effect during fetal 
life.37 Incidence of testicular cancer rises with the 
testosterone surge in puberty and peaks at 30-35 years. 
In addition to testicular cancer, our study provided 
evidence for other associations between birth defects 
and cancer diagnosed in adulthood. For example, the 
odds ratio for congenital heart defects and overall 
cancer was 1.28 (1.02 to 1.59), similar to or lower than 
those previously suggested for adults.14 35 36 Another 
example was nervous system defects, with a 15-fold 
increased risk of cancer before the age of 5, whereas 
the odds ratio for adults was reduced to 1.76 (1.16 to 
2.65). This trend has been suggested previously but 
was limited to the first 12 years of life and/or with few 
co-occurring cases.13 14
An increasing number of (non-chromosomal) birth 
defects in different organ systems have been associated 
with increased risk of cancer overall.3 5 8 9 14 Our results 
support this, and we also saw the same trend for 
chromosomal birth defects. We observed an increase in 
relative risk of overall cancer with increasing number of 
birth defects and, in addition, for some specific cancers 
such as acute lymphatic leukaemia (for chromosomal 
birth defects), soft tissue cancer, kidney cancer, central 
nervous system tumours, and other myeloid leukaemia 
(for non-chromosomal birth defects).
As expected, the increased overall cancer risk was 
lower than in previous studies limited to childhood 
cancer, but the results for children were in line 
with previous findings when stratified by age at 
diagnosis.3  4 The associations between chromosomal 
birth defects (driven mainly by Down’s syndrome) 
and cancer are well known, such as the high risks for 
leukaemia. Specifically, our estimated odds ratios of 
111 and 22 for acute myeloid leukaemia and acute 
lymphatic leukaemia, respectively, are in concordance 
with the corresponding hazard ratio estimates of 125 
and 28 recently published by Lupo et al.3 In addition, 
adults with Down’s syndrome were at increased risk 
of testicular cancer (odds ratio 4.9, 2.7 to 8.7), which 
has also been suggested previously but with less 
precision.38
implications of findings and future research
Our study showed that birth defects are associated with 
risk of cancer in adulthood as well as in adolescence 
and childhood, a finding of clinical importance for 
healthcare workers responsible for follow-up of people 
with birth defects. Surveillance for cancer in children 
with birth defects has been discussed, but thus far 
the absolute cancer risk has been regarded as too low. 
In the Nordic countries, for instance, the cumulative 
risk of any cancer in the 0-44 year age group was 
2.3% for males and 3.8% for females in 2016.39 Thus, 
the most important implication of our results is to 
provide further rationale for additional studies on the 
molecular mechanisms involved in the developmental 
disruptions underlying both birth defects and cancer.
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